It’s remarkable how genomics is being used in NHS healthcare, particularly in cancer, where tests now look at the DNA of actual tumours rather than patients. As I have covered previously for ComputerWeekly.com, lung cancer is being targeted through the National Lung Matrix Study. It’s now the case that 15-20% of lung cancer patients can receive targeted treatment based on genomics.
Gary Middleton, professor of medical oncology at the University of Birmingham and chief investigator of the National Lung Matrix Study, put it this way in my new article on this for Guardian Healthcare Professionals Network:
Lung cancer used to be a very simple disease. There were very few treatments and patients did very poorly. It’s really quite complicated now. Keeping on top of the new drugs and the new indications is difficult.
Continue reading “What makes tumours tick? Genomics pave the way for tailored treatments”